Top Markets
Coin of the day
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc.

USRM
주식 순위 #41992
U.S. Stem Cell, Inc. is a biotechnology firm dedicated to the advancement and... U.S. Stem Cell, Inc. is a biotechnology firm dedicated to the advancement and commercialization of autologous cellular therapies throughout the United States. Its core mission is to address a range of medical conditions, including both chronic and acute forms of heart damage, along with various vascular and autoimmune disorders. Among its leading experimental treatments are MyoCell, a clinical-stage therapy designed to utilize a patient's own muscle cells to regenerate scar tissue within the heart, aiming to enhance cardiac function for individuals suffering from chronic heart failure. Another significant offering is AdipoCell, a cell therapy also derived from the patient's own body, developed to combat conditions such as acute myocardial infarction, persistent heart ischemia, and ischemia affecting the lower limbs. The company's developmental pipeline also features MyoCell SDF-1, another autologous cellular therapy derived from muscle, intended to boost cardiac performance in chronic heart failure patients. Furthermore, U.S. Stem Cell is actively developing MyoCath, an innovative deflecting-tip needle injection catheter specifically engineered to deliver therapeutic cells directly into heart tissue, addressing chronic heart ischemia and congestive heart failure. Beyond its product development, the company offers a suite of services, including training programs in regenerative medicine and cell therapy for both medical professionals and patients. It also facilitates cell collection and storage, provides specialized kits for cell collection and treatment for both human and veterinary applications, and manages its own cell therapy clinic. This clinic delivers cellular treatments for a broad spectrum of conditions, such as neurological, autoimmune, orthopedic, and degenerative disorders. Previously known as Bioheart, Inc., the company adopted its current name, U.S. Stem Cell, Inc., in October 2015. Established in 1999, its corporate headquarters are situated in Sunrise, Florida.
주가
$0.00001
마지막 동기화: 2026-08-07
시가총액
$6.42K
변동 (1일)
-90.00%
변동 (1년)
-90.00%
국가
US
거래 U.S. Stem Cell, Inc. (USRM)

카테고리

B의 시가 총액을 가진 USRM의 가격
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.
USRM
$0.00001
의 시가총액 U.S. Stem Cell, Inc.(USRM)
시가총액: $6.42K
August 2026 기준으로 U.S. Stem Cell, Inc.의 시가총액은 $6.42K입니다. 이는 당사 데이터에 따르면 U.S. Stem Cell, Inc.이 세계에서 41992nd번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2008부터 2026까지 U.S. Stem Cell, Inc.의 시가총액 기록
USRM 가장 인기있는 상위 5 가지 stocks과 비교하여
USRM의 가격 자산 b b의 시장 결과
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.
$8,391.83 $6.42K
$5.383T +83,918,307,928.06%
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.
$6,895.39 $6.42K
$4.423T +68,953,876,809.40%
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.
$6,485.38 $6.42K
$4.160T +64,853,770,735.26%
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.
$5,710.55 $6.42K
$3.663T +57,105,546,852.46%
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.
$4,506.98 $6.42K
$2.891T +45,069,817,443.26%